Drug Profile
Caficrestat - Applied Therapeutics
Alternative Names: AT-001 - Applied TherapeuticsLatest Information Update: 09 Apr 2024
Price :
$50
*
At a glance
- Originator Applied Therapeutics
- Developer Applied Therapeutics; NYU Langone Medical Center
- Class Acetic acids; Anti-ischaemics; Antivirals; Benzothiazoles; Cardiovascular therapies; Fluorinated hydrocarbons; Heart failure therapies; Pyrazines; Pyridazines; Small molecules
- Mechanism of Action Aldehyde reductase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase III Cardiomyopathies; Peripheral nervous system diseases
- Phase II COVID 2019 infections
- Phase I/II Heart failure
- No development reported Myocardial infarction
Most Recent Events
- 04 Apr 2024 Efficacy and adverse events data from a phase-III ARISE-HF trial in Cardiomyopathies released by Applied Therapeutics
- 04 Jan 2024 Efficacy and adverse events data from a phase III ARISE-HF trial in Cardiomyopathies released by Applied Therapeutics
- 05 Nov 2022 Pharmacodynamics data from a preclinical trial in Diabetic cardiomyopathy presented at American Heart Association Scientific Sessions 2022 (AHA-2022)